Clinical Trial Update: A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML [Phase 1]

View source ↗

Summary

A Phase I open-label dose-escalation study of intravenous INKmune in patients with myelodysplastic syndromes or acute myeloid leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• INKmune (INKmune)

Snippet

Sponsor: Inmune Bio, Inc. | Conditions: Cancer, MDS-EB | Phase 1 | Status: TERMINATED